• Continued execution of the PNS Contract, with Stage 2 rollout comprising deployment of the next 500 licences
• Life Radiology pilot advanced into full patient deployment at the Miami clinic
• Significant U.S. growth opportunity progressed, with a submission of a confidential, multi-million-dollar project request to the U.S. House of Representatives

The December 2025 quarter was a period of sustained execution and strategic advancement for Singular Health Group Limited (ASX: SHG). The company continued to progress key initiatives across U.S. and international markets, including the scale-up of commercial deployments, deepening of government and enterprise partnerships, and the expansion of regulatory and technical capabilities. Singular Health's initial commercial agreement with Provider Network Solution (PNS) in the United States continues to progress, with 250 licenses of 3DICOM MD® deployed and a further 500 licenses commencing deployment. The pilot program with Life Radiology has now moved beyond the technical validation phase and is transitioning into full patient deployment to the Miami clinic. Singular Health also submitted a confidential, multi-million-dollar Project Request to the U.S. House of Representatives in collaboration with Florida International University (FIU), and advanced separate discussions into the final stages with FIU towards a direct engagement. The company has also progressed discussions with Verda Healthcare, a Texas-based MSO, and explored integration with Athena Health, a leading U.S. provider of cloud-based electronic health record (EHR) and practice management solutions. Singular Health achieved several key regulatory and compliance milestones, including FDA 510(k) clearance for 3DICOM MD® Cloud post period end, successful renewal of ISO 13485 certification, and continued progress toward GDPR and HITRUST compliance. The company's core IP was also independently validated, with a positive WIPO assessment confirming the novelty and strategic value of Singular's MFTP technology.

With strong momentum heading into 2026, disciplined cash management, and a significant cash runway, Singular Health is well positioned to capitalise on its commercial, regulatory, and technical progress. The PNS contract remains on track and continues to exceed expectations, the Life Radiology deployment is positioned to transform patient experience, and new commercial opportunities across PNS partner and joint venture networks, together with initiatives such as the proposed collaboration with Florida International University and the potential integration with Athena Health, reinforce a strong and growing pipeline of opportunities.